1. Home
  2. GOSS vs CMPX Comparison

GOSS vs CMPX Comparison

Compare GOSS & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gossamer Bio Inc.

GOSS

Gossamer Bio Inc.

HOLD

Current Price

$3.45

Market Cap

726.8M

Sector

Health Care

ML Signal

HOLD

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$5.14

Market Cap

752.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOSS
CMPX
Founded
2015
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
726.8M
752.4M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
GOSS
CMPX
Price
$3.45
$5.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
10
Target Price
$8.60
$13.44
AVG Volume (30 Days)
2.8M
2.0M
Earning Date
11-05-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$44,051,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$1.33
52 Week High
$3.60
$5.86

Technical Indicators

Market Signals
Indicator
GOSS
CMPX
Relative Strength Index (RSI) 64.60 55.13
Support Level $3.25 $5.13
Resistance Level $3.45 $5.76
Average True Range (ATR) 0.19 0.34
MACD 0.02 -0.02
Stochastic Oscillator 83.61 34.96

Price Performance

Historical Comparison
GOSS
CMPX

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Share on Social Networks: